Mersana Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview

Mersana Therapeutics

05/05/2023 17:57

* Mersana Therapeutics Inc  MRSN.OQ   MRSN.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 9. 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 798.1% increase in revenue to $18.286 million from $2.04
million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Mersana
Therapeutics Inc
is for a loss of 44 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mersana
Therapeutics Inc is $14.5​, above​ its last closing price
of $7.04. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.47       -0.50      -0.44     Beat    12.8
 Sep. 30 2022  0.04        -0.09      -0.61     Missed  -577.8
 Jun. 30 2022  -0.53       -0.52      -0.55     Missed  -5.8​
 Mar. 31 2022  -0.32       -0.32      -0.59     Missed  -85.2
 ​​Dec.        -0.66       -0.67      -0.68     Missed  -1.7
 31 2021                                                
 Sep. 30 2021  -0.58       -0.58      -0.63     Missed  -8.6​
 Jun. 30 2021  -0.50       -0.50      -0.59     Missed  -18.4
 Mar. 31 2021  -0.40       -0.39      -0.50     Missed  -26.6
 This summary was machine generated May 5 at 16:57 GMT.  All
figures in US dollars  unless otherwise stated